Ibrutinib‐induced severe liver injury

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nandikolla, Amara G., Derman, Olga, Nautsch, Deborah, Liu, Qiang, Massoumi, Hatef, Venugopal, Sangeetha, Braunschweig, Ira, Janakiram, Murali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458017/
https://www.ncbi.nlm.nih.gov/pubmed/28588800
http://dx.doi.org/10.1002/ccr3.881
_version_ 1783241664357203968
author Nandikolla, Amara G.
Derman, Olga
Nautsch, Deborah
Liu, Qiang
Massoumi, Hatef
Venugopal, Sangeetha
Braunschweig, Ira
Janakiram, Murali
author_facet Nandikolla, Amara G.
Derman, Olga
Nautsch, Deborah
Liu, Qiang
Massoumi, Hatef
Venugopal, Sangeetha
Braunschweig, Ira
Janakiram, Murali
author_sort Nandikolla, Amara G.
collection PubMed
description Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a patient with relapsed/refractory CLL.
format Online
Article
Text
id pubmed-5458017
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54580172017-06-06 Ibrutinib‐induced severe liver injury Nandikolla, Amara G. Derman, Olga Nautsch, Deborah Liu, Qiang Massoumi, Hatef Venugopal, Sangeetha Braunschweig, Ira Janakiram, Murali Clin Case Rep Case Reports Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a patient with relapsed/refractory CLL. John Wiley and Sons Inc. 2017-03-15 /pmc/articles/PMC5458017/ /pubmed/28588800 http://dx.doi.org/10.1002/ccr3.881 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nandikolla, Amara G.
Derman, Olga
Nautsch, Deborah
Liu, Qiang
Massoumi, Hatef
Venugopal, Sangeetha
Braunschweig, Ira
Janakiram, Murali
Ibrutinib‐induced severe liver injury
title Ibrutinib‐induced severe liver injury
title_full Ibrutinib‐induced severe liver injury
title_fullStr Ibrutinib‐induced severe liver injury
title_full_unstemmed Ibrutinib‐induced severe liver injury
title_short Ibrutinib‐induced severe liver injury
title_sort ibrutinib‐induced severe liver injury
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458017/
https://www.ncbi.nlm.nih.gov/pubmed/28588800
http://dx.doi.org/10.1002/ccr3.881
work_keys_str_mv AT nandikollaamarag ibrutinibinducedsevereliverinjury
AT dermanolga ibrutinibinducedsevereliverinjury
AT nautschdeborah ibrutinibinducedsevereliverinjury
AT liuqiang ibrutinibinducedsevereliverinjury
AT massoumihatef ibrutinibinducedsevereliverinjury
AT venugopalsangeetha ibrutinibinducedsevereliverinjury
AT braunschweigira ibrutinibinducedsevereliverinjury
AT janakirammurali ibrutinibinducedsevereliverinjury

Ejemplares similares